动力学惰性铂（IV）羟基配合物的羧化反应。迈向口服活性铂（IV）抗肿瘤药物的插曲。 - Suppr

Suppr

超能文献

Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents.

作者信息

Giandomenico C M, Abrams M J, Murrer B A, Vollano J F, Rheinheimer M I, Wyer S B, Bossard G E, Higgins J D

出版信息

Inorg Chem. 1995 Mar;34(5):1015-21. doi: 10.1021/ic00109a004.

DOI:10.1021/ic00109a004

PMID:20000850

Abstract

摘要

相似文献

Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents.动力学惰性铂（IV）羟基配合物的羧化反应。迈向口服活性铂（IV）抗肿瘤药物的插曲。

Inorg Chem. 1995 Mar;34(5):1015-21. doi: 10.1021/ic00109a004.

The effect of antitumor trans-[PtCl2(E-iminoether)2] on B-->Z transition in DNA.抗肿瘤反式-[PtCl2（E-亚氨基醚）2]对DNA中B→Z转变的影响。

Anticancer Drug Des. 1997 Jun;12(4):295-309.

Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.轴向和赤道配体对反式-1R,2R-二氨基环己烷铂(IV)配合物抗肿瘤活性的调节作用。

Anticancer Drug Des. 1994 Apr;9(2):139-51.

The influence of tumour microenvironmental factors on the efficacy of cisplatin and novel platinum(IV) complexes.肿瘤微环境因素对顺铂及新型铂（IV）配合物疗效的影响。

Biochem Pharmacol. 2005 Oct 15;70(8):1137-46. doi: 10.1016/j.bcp.2005.07.016.

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.双乙酸根-氨-二氯-环己胺铂(IV)的临床前抗肿瘤评估：一种口服活性铂类药物

Cancer Res. 1993 Jun 1;53(11):2581-6.

Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo.具有氨/胺载体配体构型的四价铂配合物：体内铂耐药性的规避

Anticancer Drug Des. 1994 Dec;9(6):495-509.

Synthesis, characterization, in vitro antitumoral investigations and interaction with plasmid pBR322 DNA of R2eddp-platinum(IV) complexes (R = Et, n-Pr).R2eddp-铂（IV）配合物（R = Et，n-Pr）的合成、表征、体外抗肿瘤研究及与质粒 pBR322 DNA 的相互作用。

Dalton Trans. 2009 Dec 28(48):10720-6. doi: 10.1039/b911597h. Epub 2009 Aug 27.

Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.人类癌细胞系对铂（II）与铂（IV）抗癌药物的化学敏感性和耐药性特征分析。

Anticancer Drugs. 2009 Aug;20(7):559-72. doi: 10.1097/CAD.0b013e32832d513b.

Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).轴向配体和脂环大小调节氨/环烷基胺-铂(IV)配合物在对顺二氯二氨铂(II)或反式-1R,2R-1S,2S-二氨基环己烷四氯铂(IV)耐药的肿瘤细胞中的活性和生化药理学。

Cancer Res. 1994 Sep 1;54(17):4691-7.

Cell proliferation inhibition and antitumor activity of novel alkyl series of diorganotin(IV) compounds.新型二有机锡（IV）化合物烷基系列的细胞增殖抑制及抗肿瘤活性

J Appl Toxicol. 2008 May;28(4):430-8. doi: 10.1002/jat.1290.

引用本文的文献

Synthesis, crystal structural description, DNA binding, molecular docking, and anticancer evaluation of the novel platinum(IV) supramolecular complex.新型铂（IV）超分子配合物的合成、晶体结构描述、DNA结合、分子对接及抗癌评估

BMC Chem. 2025 Apr 18;19(1):102. doi: 10.1186/s13065-025-01472-8.

The full spectrum of SLC22 OCT1 mutations illuminates the bridge between drug transporter biophysics and pharmacogenomics.SLC22 OCT1 突变的全貌阐明了药物转运蛋白生物物理学与药物基因组学之间的桥梁。

Mol Cell. 2024 May 16;84(10):1932-1947.e10. doi: 10.1016/j.molcel.2024.04.008. Epub 2024 May 3.

Promising Anticancer Prodrugs Based on Pt(IV) Complexes with Bis-organosilane Ligands in Axial Positions.基于轴向带有双有机硅烷配体的Pt(IV)配合物的新型抗癌前药

J Med Chem. 2024 Apr 25;67(8):6410-6424. doi: 10.1021/acs.jmedchem.3c02393. Epub 2024 Apr 9.

Oxidation of the Platinum(II) Anticancer Agent [Pt{(-BrCF)NCHCHNEt}Cl(py)] to Platinum(IV) Complexes by Hydrogen Peroxide.过氧化氢将铂（II）抗癌剂[Pt{(-BrCF)NCHCHNEt}Cl(py)]氧化为铂（IV）配合物。

Molecules. 2023 Sep 1;28(17):6402. doi: 10.3390/molecules28176402.

The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics.OCT1（溶质载体家族22成员1，SLC22A1）突变的全貌将转运体生物物理学与药物基因组学联系起来。

bioRxiv. 2023 Jun 7:2023.06.06.543963. doi: 10.1101/2023.06.06.543963.

Computational Exploration of the Synergistic Anticancer Effect of a Multi-Action Ru(II)-Pt(IV) Conjugate.计算探索多作用钌（II）-铂（IV）缀合物的协同抗癌作用。

Inorg Chem. 2022 Aug 15;61(32):12903-12912. doi: 10.1021/acs.inorgchem.2c02223. Epub 2022 Jul 28.

Potential Anticancer Activities and Catalytic Oxidation Efficiency of Platinum(IV) Complex.铂（IV）配合物的潜在抗癌活性和催化氧化效率。

Molecules. 2022 Jul 9;27(14):4406. doi: 10.3390/molecules27144406.

Microwave-Assisted Synthesis: Can Transition Metal Complexes Take Advantage of This "Green" Method?微波辅助合成：过渡金属配合物能利用这种“绿色”方法吗？

Molecules. 2022 Jun 30;27(13):4249. doi: 10.3390/molecules27134249.

In Vitro Nephrotoxicity Studies of Established and Experimental Platinum-Based Compounds.已确立的和实验性铂类化合物的体外肾毒性研究

Biomedicines. 2021 Aug 18;9(8):1033. doi: 10.3390/biomedicines9081033.

Platinum(IV)-azido monocarboxylato complexes are photocytotoxic under irradiation with visible light.含叠氮基的顺铂羧酸复合物在可见光照射下具有光细胞毒性。

Dalton Trans. 2021 Aug 4;50(30):10593-10607. doi: 10.1039/d1dt01730f.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验